LA Private

August 14, 2024

Stocks of the Hour: Immutep, LiveHire, Forbidden Foods, Estrella Resources

To register for Friday’s webinar click here. Immutep (ASX:IMM) has initiated a Phase I clinical trial to evaluate the safety and efficacy of IMP761, a novel LAG-3 agonist antibody. IMP761 is designed to restore immune system balance by enhancing the hindering function of LAG-3 on T cells, thereby addressing the underlying cause of numerous autoimmune

Stocks of the Hour: Immutep, LiveHire, Forbidden Foods, Estrella Resources Read More »

ASX up 0.7% near noon: US inflation data provides optimism

At 11:35am, the S&P/ASX 200 is 0.7 per cent higher at 7,881.90, driven by a strong performance from the utilities sector, particularly AGL Energy, whose earnings exceeded expectations. This positive market sentiment was further buoyed by optimistic investor expectations of US interest rate cuts, following upbeat US inflation data. The producer price index’s modest 0.1% July

ASX up 0.7% near noon: US inflation data provides optimism Read More »

Immuteps groundbreaking autoimmune disease treatment enters clinical trials

In a potential game-changer for millions of people worldwide, Immutep (ASX:IMM; NASDAQ:IMMP) has initiated the first human trials of IMP761, a novel agonist LAG-3 antibody designed to treat autoimmune diseases. The commencement of this Phase I trial marks a significant milestone for Immutep and the broader field of autoimmune disease research. By targeting the underlying

Immuteps groundbreaking autoimmune disease treatment enters clinical trials Read More »

China’s credit crunch deepens

Credit data shows China has slipped into a form of credit trap, with new loans in July hitting their lowest level in nearly 15 years, at a time when interest rates are at record lows. The slump in new loans comes despite two interest rate cuts and reductions in reserve ratios for banks this year.

China’s credit crunch deepens Read More »